ReviewEye (London, England)2023
Retinoblastoma and vision.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Analysing Differential Alternative Splicing Events and Their Impact on Retinoblastoma Progression Using RNA-seq Metadata.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Management of Retinoblastoma: A Challenge in Pediatric Ophthalmology.Life (Basel, Switzerland) · 2026Review
- Nanotherapeutic potential in glaucoma associated ocular cancers.Discover oncology · 2026Review
- Intra-arterial chemotherapy for retinoblastoma: a structured narrative review.World journal of pediatric surgery · 2026Review
- Retinoblastoma survival trend: a 30-year analysis from a referral single center in Iran.International journal of retina and vitreous · 2025Article
- Ocular manifestations in pediatric tumor suppressor gene mutations: a case series and literature review of RB1, NF1, NF2, VHL, and TSC.BMC pediatrics · 2025Review
- Retinoblastoma management in China: clinical challenges.International journal of ophthalmology · 2025Review
- Retinoblastoma in Ceara: An epidemiological study in a Brazilian pediatric oncology referral center.Arquivos brasileiros de oftalmologia · 2024Article
- Progress of Cancer Stem Cells in Retinoblastoma.Current stem cell research & therapy · 2024Review
- MiR-452-5p facilitates retinoblastoma cell growth and invasion via the SOCS3/JAK2/STAT3 pathway.Journal of biochemical and molecular toxicology · 2023Article
- The Most-Cited Articles on Retinoblastoma: A Fifty-Year Perspective.Vision (Basel, Switzerland) · 2023Article
- Long non-coding RNAs involved in retinoblastoma.Journal of cancer research and clinical oncology · 2023Review
- Nanotechnology for Pediatric Retinoblastoma Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Myopia and Other Visual Disorders in Children.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment of vision has a growing importance in the management of retinoblastoma in the era of globe-conserving therapy, both prior to and after treatment. As survival rates approach 98-99% and globe salvage rates reach ever-higher levels, it is important to provide families with information regarding the visual outcomes of different treatments. We present an overview of the role of vision in determining the treatment given and the impact of complications of treatment. We also discuss screening and treatment strategies that can be used to maximise vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.